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Although whole-genome association studies using tagSNPs are a powerful approach for detecting common variants, they are underpow-
ered for detecting associations with rare variants. Recent studies have demonstrated that common diseases can be due to functional var-
iants with a wide spectrum of allele frequencies, ranging from rare to common. An effective way to identify rare variants is through direct
sequencing. The development of cost-effective sequencing technologies enables association studies to use sequence data from candidate
genes and, in the future, from the entire genome. Although methods used for analysis of common variants are applicable to sequence
data, their performancemight not be optimal. In this study, it is shown that the collapsingmethod, which involves collapsing genotypes
across variants and applying a univariate test, is powerful for analyzing rare variants, whereas multivariate analysis is robust against
inclusion of noncausal variants. Bothmethods are superior to analyzing each variant individually with univariate tests. In order to unify
the advantages of both collapsing and multiple-marker tests, we developed the Combined Multivariate and Collapsing (CMC) method
and demonstrated that the CMC method is both powerful and robust. The CMC method can be applied to either candidate-gene or
whole-genome sequence data.Introduction
For the mapping of common disease susceptibility genes,
hundreds of thousands of SNPs are genotyped to facilitate
genome-wide association studies in either family- or popu-
lation-based data. In order for this study design to be
successful, the common disease common variant (CDCV)
hypothesis must hold true. The CDCV hypothesis asserts
that common diseases are caused by common variants
with small to modest effects.1–4 This is currently the
most popular theory underlying complex-disease etiology.
A well-known example supporting this hypothesis is the
APOE gene, in which a single common allele ð34Þ confers
high risk of Alzheimer disease and heart disease.5
The HapMap project and advances in large-scale SNP
genotyping facilitate the identiﬁcation of disease-suscepti-
bility genes through indirect linkage disequilibrium (LD)
mapping. The nonrandom association (i.e., LD) of SNPs
is appealing for disease-gene mapping, because a subset
of SNPs (tagSNPs) can capture the information of corre-
lated SNPs that are not genotyped, thus vastly reducing
the number of SNPs that need to be genotyped for an asso-
ciation study when the CDCV hypothesis holds.1,6,7 An
alternative theory is the common disease rare variant
(CDRV) hypothesis, which states that for complex traits
there is extreme allelic heterogeneity and that disease etiol-
ogy is caused collectively by multiple rare variants with
moderate to high penetrances.2,4 Studies based on evolu-
tion theories have demonstrated that for complex diseases,
allelic heterogeneitymight be extensive, withmultiple sus-
ceptibility alleles of independent origin.8,9 Analysis based
on HapMap data has illustrated that rare variants are
more likely to be disease predisposing than are commonvariants.10 There is also empirical evidence supporting
this hypothesis; e.g., multiple rare variants have also
been recently identiﬁed to be associated with low plasma
levels of HDL cholesterol,11–15 obesity (MIM 601665),16 co-
lorectal adenomas (MIM 608456),17 and schizophrenia
(MIM 181500).18 Although there is substantial evidence
that both the CDRV and the CDCV hypotheses are valid,
probably a more realistic model for complex traits is that
functional variants have a wide spectrum of allele frequen-
cies, which range from rare to common even within the
same susceptibility gene.2
Recent association studies have been successful for
a number of traits, such as age-related macular degenera-
tion (AMD [MIM 603075])19,20 and Crohn disease (MIM
266600).21 However, critical assumptions for the efﬁcient
detection of associations through LD mapping are that
for a speciﬁc susceptibility locus there is only low-level al-
lelic heterogeneity and that the variants are common.6,22
In the presence of allelic heterogeneity, although the
power of linkage analysis is not inﬂuenced, association
studies based on LD mapping will inevitably be low-pow-
ered.10,23 Low frequencies of functional variants result in
low r2 values, with tagSNPs ofR 5% frequency, and there-
fore, the power of the indirect LD-mapping approach is
low. Alternative approaches are necessary to efﬁciently
identify loci with extreme allelic heterogeneity, i.e., multi-
ple rare variants. Directly sequencing candidate genes—or,
in the future, entire genomes—instead of genotyping
tagSNPs is an optimal approach for the identiﬁcation of
rare variants associated with disease susceptibility.13 Re-
cently, candidate-gene resequencing was employed to
discover variants in the population for the association of
complex traits.11–17 A major sequencing effort is currently1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
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being carried out by an international consortium to se-
quence at least 1000 genomes, in order to produce the
most detailed map of human genetic variations for the
support of disease studies (1000 Genomes Project, Interna-
tional Consortium).
Statistical methods for the detection of associations of
common variants have been extensively developed and suc-
cessively applied to numerous studies of complex traits.
However, methods for statistical analysis of rare variants
are limited. Somemethods used for analysis of commonvar-
iants are readily applicable to rare variants, but their perfor-
mancemaynotbeoptimal. In thenext fewyears, sequencing
technology (e.g., 454 and Solexa) will enable the production
of large quantities of sequencedata on largenumbers of indi-
viduals and allow for the cost-effective identiﬁcation of rare
variants. This data will enable researchers to investigate the
role that rare variants play in disease etiology. In addition
touncovering functional variants, sequence datawill also re-
veal many variants that are not functional. Bioinformatics
tools24 can be used to classify variants as functional or non-
functional or to quantify the functionality of the variants.
In this article, new methods for the analysis of sequenc-
ing data, which are robust and powerful in the presence of
allelic heterogeneity and low allele frequencies, are devel-
oped, and their performance is evaluated. Although under-
standing the effect of individual rare variants is ultimately
important, an effective ﬁrst approach is to identify the
genes that are involved in the disease etiology. One ap-
proach is the single-marker test, whereby individual variant
sites within a gene are tested for an association with the
disease outcome, with standard univariate statistical tests
used (e.g., c2 test, Fisher’s exact test, or Cochran Armitage
test for trend) and with the family-wise error rate (FWER)
controlled by a multiple-comparison correction (e.g., Bon-
ferroni, permutation). Another approach is to perform
a multiple-marker test, which tests multiple variant sites
simultaneously with the use of multivariate methods,
such as the Fisher product method,25 Hotelling’s T2
test,26,27 or logistic regression. Both single-marker andmul-
tiple-marker tests involvemultiplicity (i.e.,multiple-testing
correction or multiple degrees of freedom), which will re-
duce power. On the other hand, collapsingmethods, which
combine information across multiple variant sites, could
enrich the association signals and at the same time reduce
the number of the test’s degrees of freedom. However, col-
lapsing nonfunctional variants together with functional
variants could adversely affect power. In this article, the per-
formance of single-marker tests, multiple-marker tests, and
collapsingmethods are investigated analytically and empir-
ically. Additionally, the effects ofmisclassiﬁcationonpower
are evaluated. Misclassiﬁcation can occur when noncausal
variants are included in the analysis orwhen functional var-
iants are excluded from the analysis because the region has
not been sequenced or the variants are falsely deemed non-
functional through bioinformatics tools. It is demonstrated
that collapsing methods are potentially more powerful
than are single-marker andmultiple-marker tests; however,312 The American Journal of Human Genetics 83, 311–321, Septemcollapsing methods are not always robust to misclassiﬁca-
tion of nonfunctional variants, and power loss can be sub-
stantial. Although they are less powerful than collapsing
methods, multivariate tests aremore robust in the presence
of misclassiﬁcation of nonfunctional variants. In order to
unify the advantages of both collapsing and multiple-
marker tests, the Combined Multivariate and Collapsing
(CMC) method is developed. This CMC method is shown
to be both powerful and robust against misclassiﬁcation.
Material and Methods
In this article, both analytical and empirical results are presented.
Simulations were used for empirical evaluation of type I error and
the effect of LD on power; all other power calculations were carried
out analytically. Although approximations of prevalence and
wild-type penetrance are described here for easier interpretation,
only exact analytical calculations were implemented.
Genetic Model
Assume that within a locus there are M variants that can indepen-
dently cause disease susceptibility. The term ‘‘locus’’ refers to the
unit inwhich the variantswill be collectively analyzed. The variants
can reside within a gene or a single genomic region. Usually, rare
mutations occur on different haplotypes within a locus8,9 and,
therefore, correlation between variants is low. For the analytical
calculations, it is assumed that variants are independent. Each of
the variants has two alleles, denoted as Ai and ai, i ¼ 1,2,.,M, in
which Ai is the rare and high-risk allele and has an allele frequency
of pi. The total frequencyof the rare variants in a locus is p ¼
PM
i¼1 pi.
LetGk, k ¼ 0,1,2 denote the genotypes aa, Aa, andAA, respectively.
The genotype frequencies under Hardy-Weinberg Equilibrium
(HWE) at the ith variant site are piðG0Þ ¼ ð1 piÞ2,
piðG1Þ ¼ 2pið1 piÞ and piðG2Þ ¼ p2i . Let the penetrances of geno-
types at the ith variant site be represented by fki for genotypes
Gk, k ¼ 0,1,2. The locus wild-type penetrance, denoted by f0, is the
probability of an individual being affected if the genotypes across
all variant sites are wild-type aa. The overall and individual wild-
type penetrances satisfy f0 ¼ 1
QM
i¼1ð1 f0iÞ: For low wild-type
penetrances at individual variant sites, the higher-order product
terms can be ignored, and the relationship can be approximated
by f0 ¼
PM
i¼1 f0i: If the assumption ismade thatwild-type genotypes
at different sites have the same penetrance, the relationship can be
simpliﬁed to f0 ¼ Mf0i: The locus relative risk (RR) at the ith variant
site is deﬁned as g1i ¼ f1i/f0, g2i ¼ f2i/f0. For the additive model,
g2i ¼ 2g1i  1; for the multiplicative model, g2i ¼ g21i; for the dom-
inant model, g2i ¼ g1i; for the recessive model, g1i ¼ 1. The preva-
lence of thedisease causedbyeach individual variant is calculated as
Ki ¼
X2
k¼0
piðGkÞfki:
Under the heterogeneity model, the prevalence caused by the
entire locus is given by
K ¼ 1
YM
i¼1
ð1 KiÞ:
If individual prevalences due to a single variant are low, the
higher-order product terms can be ignored and the totalber 12, 2008
prevalence can be approximated by the sum of the individual
prevalences: K ¼PMi¼1Ki:
As a result of allelic heterogeneity, affected individuals can have
the same phenotype due to different causal variants. The propor-
tion of individuals affected as a result of the ith variant in the
ascertained cases is given by
pi ¼ KiXM
j¼1Kj
:
Individuals with diseases due to the ith variant are members of
the ith ‘‘group,’’ with a total of M groups in the ascertained cases,
and the relative sample size of the ith group is pi. For the i
th group,
the expected genotype frequency at the ith variant site in cases is
piðGk j giÞ ¼ piðGkÞfki
Ki
, k ¼ 0,1,2:
The expected frequency of genotype Gk at the i
th variant site
across all M groups in cases is given by
pDi ðGkÞ ¼ pipðGk j giÞ þ ð1 piÞpðGkÞ, k ¼ 0,1,2:
The controls are disease-free, and the expected genotype fre-
quencies at the ith variant site in controls is given by
pNi ðGkÞ ¼
piðGkÞ

1 fki

1 Ki , k ¼ 0,1,2:
Informationontheexpectedgenotype frequencies at eachvariant
site in the sample can be used for various methods to analytically
calculate the power to detect an association. The focus in this article
is the omnibus test, which provides an association test of the entire
locus and is not focused on any speciﬁc variant within the locus.
Single-Marker Test
One approach of association studies is to test each variant site
individually with the use of a univariate test and assess the signif-
icance of the omnibus test after correction for multiple compari-
sons. For univariate tests, a 233 contingency table can be con-
structed to compare genotype frequencies at each variant site in
cases and controls. Because an observation of individuals that
are homozygous for the high-risk rare allele is extremely rare, AA
genotypes are collapsedwith Aa genotypes, and a 232 table is con-
structed. For an equal number of cases and controls,NA ¼ NA ¼ N,
the classical Pearson c2 statistic28 for testing equal genotype
frequencies in cases and controls is given by
X2i ¼ N
(hbpDi ðaaÞ  bpNi ðaaÞi2bpDi ðaaÞ þ bpNi ðaaÞ
þ
hbpDi ðAaÞ þ bpDi ðAAÞ  bpNi ðAaÞ  bpNi ðAAÞi2bpDi ðAaÞ þ bpDi ðAAÞ þ bpNi ðAaÞ þ bpNi ðAAÞ
)
in which each bpi is the observed genotype frequency at the ith var-
iant site in cases and controls. The power of the test is dependent
on the noncentrality parameter (NCP), denoted as vi, of a noncen-
tral c21 distribution, and the NCP is given by
ni ¼ N
(
pDi ðaaÞ  pNi ðaaÞ
2
pDi ðaaÞ þ pNi ðaaÞ
þ

pDi ðAaÞ þ pDi ðAAÞ  pNi ðAaÞ  pNi ðAAÞ
2
pDi ðAaÞ þ pDi ðAAÞ þ pNi ðAaÞ þ pNi ðAAÞ
)
:The AmericanThepower todetect anassociationat the ithvariant site at levela is
hi ¼ Pr

c21ðniÞRc21;1a

:
BecauseM tests are performed atM variant sites, it is necessary to
correct for multiple comparisons in order to control the FWER.
Because all rare variants are assumed to be independent, a Bonfer-
roni correction is used, and after controlling for the FWER, the
power of the ith test is
hBi ¼ Pr

c21ðniÞRc21;1a=M

:
The power of the omnibus test for the locus is given by
hS ¼ 1
YM
i

1 hBi

:
Multiple-Marker Test
Another approach for the study of association is to test all variants
simultaneously with the use of a multivariate test; e.g., the Fisher
productmethod, Hotelling’s T2 test, ormultiple logistic regression.
Hotelling’s T2 test is used as an example of multivariate tests, and
the power is calculated analytically for the analysis of rare variants.
Following Xiong et al.,27 an indicator variable is deﬁned for the
genotype at the ith variant site for the jth individual in the case
population:
Xji ¼
1
0
1
Genotype is AA
Genotype is Aa
Genotype is aa
8<:
Similarly, Yji is deﬁned for the control population. Let Xj ¼
(Xj1,.,XjM)
T, Yj ¼ (Yj1,., YjM)T. Then Xi ¼ 1=NA
PNA
j¼1 Xji, Yi ¼
1=NA
PNA
j¼1 Yji and X ¼ ðX1,.,XMÞT , Y ¼ ðY1,.,YMÞT . The covari-
ance matrix of the pooled sample for the indicator variables across
M variants is given by
S ¼ 1
NA þ NA  2
(XNA
j¼1

Xj X

Xj X
TþXNA
j¼1

Yj  Y

Yj  Y
T)
:
Hotelling’s T2 statistic is deﬁned as
T2 ¼ NANA
NA þNA
ðX YÞTS1ðX YÞ:
Under the null hypothesis that none of the variants is associated
withdisease susceptibility, fora large sample sizeofcases andcontrols,
NA þNA M  1
MðNA þ NA  2Þ
T2
is asymptotically distributed as an F distribution, with M and
NA þNA M  1 degrees of freedom. Under the alternative hy-
pothesis that at least one of the variants is associated with the dis-
ease, the T2 statistic is asymptotically distributed as a noncentral
c2M distribution,withMdegreesof freedom,and theNCP is givenby
nH ¼ mT
 
1
NA
X
A
þ 1
NA
X
A
!1
m,
in which m is the vector of expected difference between cases and
controls, m¼ (m1,.,mM)T, and mi ¼ E½Xi E½Yi

. The covariancema-
trices, SA for cases and SA for controls, can be simpliﬁed under the
assumption of independence of the rare variants. The ith diagonalJournal of Human Genetics 83, 311–321, September 12, 2008 313
element of the matrix is the variance of the indicator variable at
the ith variant site, and off-diagonal elements of the matrix are
zero. From the expected genotype frequencies at each variant
site, pDi ðGkÞ for cases and pNi ðGkÞ for controls, m, SA, and SA can
be calculated, and the power to detect an association for at least
one variant is given by
hH ¼ Pr

c2MðnHÞRc2M,1a

:
Collapsing Method
Given that single-marker tests involve correcting for multiple
comparisons and that multiple-marker tests can have a large num-
ber of degrees of freedom, another approach, which collapses the
genotypes across variants and results in enriched signals and a
reduced number of degrees of freedom, is proposed.
For this method, deﬁne an indicator variable X for the jth case
individual as
Xj ¼ 1 rare variants present0 otherwise

Yj is similarly deﬁned for control individuals. Due to the rarity of
variants, the probability of carrying more than one variant for
an individual is low, and the method collapses genotypes across
all variants, such that an individual is coded as 1 if a rare allele is
present at any of the variant sites and as 0 otherwise. The detection
of an association ofmultiple rare variants is transformed into a test
of whether the proportions of individuals with rare variants in
cases and controls differ. Let fA and fA denote the frequencies of
individuals carrying rare variants, in cases and controls, respec-
tively. The probability of no variants at all sites in the ith group
in cases is given by
li ¼ piðaa j giÞ
Y
jsi
pjðaaÞ: (1)
Summing over all groups, the proportion of individuals with at
least one variant in cases is given by
fA ¼ 1
XM
i¼1
ðpiliÞ:
In controls, the probability of carrying no variants at allM sites isQM
i¼1p
N
i ðaaÞ, and therefore, the proportion of rare-variant carriers
in controls is given by
fA ¼ 1
YM
i¼1
pNi ðaaÞ: (2)
The classic Pearson c2 statistic can be used to test the null hy-
pothesis that fA ¼ fA, and the NCP of the noncentral c21 distribu-
tion is
nc ¼ N
"
ðfA  fAÞ2
fA þ fA
þ ðfA  fAÞ
2
2 fA  fA
#
:
The power of the c2 test for the collapsing method is given by
hc ¼ Pr

c21ðncÞRc21,1a

:
CMC Method
The CMC method is a uniﬁed approach that combines collapsing
and multivariate tests. For the CMC method, markers are divided314 The American Journal of Human Genetics 83, 311–321, Septeminto subgroups on the basis of predeﬁned criteria (e.g., allele
frequencies), and within each group, marker data are collapsed.
A multivariate test (e.g., Hotelling’s T2 test) is then applied for
analysis of the groups of marker data. Suppose the M markers at
the locus are classiﬁed into k groups, {gj, j ¼ 1,.,k}, and that the
number of markers in group gj is nj. Within gj, the nj markers in
the set are collapsed as described in the previous section (Collaps-
ingMethod). Collapsing is carried out for each of the groups in the
same manner. For those groups in which the number of markers
equals 1, no collapsing is necessary. A multivariate test can then
be applied to the data, in which within each group the individuals
are coded as either 1 (a carrier of one or more variants) or 0 (wild-
type).WithHotelling’s T2 test used, the power of the CMCmethod
is calculated on the k dimensional data in the same manner as
described in the Multiple-Marker Test section.
Misclassiﬁcation
Two types of misclassiﬁcations are considered: inclusion of non-
functional variants and exclusion of functional variants. First,
consider inclusion of W nonfunctional variants in the analysis.
For the single-marker test, the power to detect an association at
nonfunctional variant sites is equal to a and the total number of
tests is M þ W. For Hotelling’s T2 test, the mean vector m and
covariance matrices SA and SA are modiﬁed by appending the
zero vector of length W to the m vector and adding variances of
nonfunctional variants to the diagonal entries of the covariance
matrices SA and SA. For the collapsing method, the genotype
frequencies of nonfunctional variants are included in Equation
(1), for cases, and in Equation (2), for controls, to calculate fA
and fA. For the CMC method, the modiﬁcation is made within
each collapsing group and then the power of Hotelling’s T2 test
is calculated.
For the case in which T functional variants are excluded from
the analysis, the power calculations for the single-marker test,
Hotelling’s T2 test, and the collapsing method are carried out in
the same manner, except that onlyM  Tout ofM variants are an-
alyzed. The number of tests for the single-marker test isM T, and
the number of degrees of freedom for Hotelling’s T2 test is M  T.
The collapsing method remains a univariate test in this situation.
For the CMC method, the power of Hotelling’s T2 is calculated on
the basis of the modiﬁed data within each collapsing group.
Effects of Linkage Disequilibrium
Simulation was used to investigate the effect of LD on power for
the single-marker test, Hotelling’s T2 test, and the collapsing
method. The locus has six variants, with a total allele frequency
of 0.05. Four of the variants have an allele frequency of 0.01 and
are on different haplotypes. Each of the remaining two variants,
with allele frequencies of 0.005, is on one of the haplotypes where
a variant with allele frequency of 0.01 resides; there is complete LD
between these variants (r2z0:5). For comparison purposes, a sec-
ond simulation was carried out, in which all variants were on sep-
arate haplotypes. For generating the data, two haplotypes were
randomly sampled and assigned to either case or control status
on the basis of an additive model with a locus RR of 2.0, assuming
that variants on different sites cause the disease independently.
The process was repeated until a sample of 250 cases and 250
controls was obtained, and the single-marker test, Hotelling’s T2
test, and the collapsing method were applied to the generated
sample. One thousand replicates were generated, and the power
was evaluated for an a level of 0.001.ber 12, 2008
Evaluation of Type I Error Rate
In order to evaluate the type I error rate for each test, simulation
was used to generate data under the null hypothesis of no associ-
ation between variants and disease status. Genotypes for each of
the M variants within a locus were generated on the basis of
population allele frequencies. This sequence of M genotypes was
randomly assigned either case or control status. This process was
repeated until the desired sample sizes for cases (NA) and controls
(NA) were obtained for each replicate, and the tests of interest were
performed on the data set. This process was repeated for 5000 rep-
licates. It was then evaluated whether or not each replicate had a
p value% 0.05. The type I error rate was estimated by the propor-
tion of replicates with a p value% 0.05. A type I error rate > 0.05
signiﬁes a higher false-positive rate, and conversely, a type I error
rate < 0.05 indicates a conservative test.
Parameters
In order to evaluate power and type I error rate, total sample sizes
of 500 and 2000 were used, with an equal number of cases and
controls. For the analysis, total locus variant frequencies of 0.05
and 0.01 were utilized, with each locus composed of 5–20 rare var-
iants with equal or unequal frequencies. The power at the a level
of 0.001 was evaluated at the locus RRs of 1.5, 2.0, and 3.0 for
the additive model, in which the locus wild-type penetrance f0 ¼
0.01. For comparison purposes, the power was also calculated at
the locus RR of 2.0 for the multiplicative, dominant, and recessive
models. Unless otherwise stated, the results are given for a sample
size of 250 cases and 250 controls, for a total locus variant fre-
quency of 0.05, with ten variants of equal frequency and a locus
RR of 2.0 under the additive model.
Results
Evaluation of Type I Error
The type I error rate is well controlled and slightly conser-
vative for Hotelling’s T2 test and the collapsing method
(Table 1). This is not the case when logistic regression is
used for the multiple-marker test and the likelihood-ratio
test is performed on the basis of an asymptotic c2 distribu-
tion. Logistic regression is anticonservative, and type I
Table 1. Type I Error Rates at the a Level of 0.05 for Data
Analyzed with and without Collapsing
Freq.
No. of
Variants
Collapsing and
Logistic Reg.
Collapsing and
Pearson c2
Hotelling’s
T2
Logistic
Reg.
0.05a 5 0.054 0.033 0.045 0.074
10 0.051 0.032 0.028 0.115
20 0.048 0.029 0.010 0.204
0.01b 5 0.051 0.032 0.044 0.084
10 0.054 0.034 0.020 0.115
20 0.054 0.032 0.006 0.191
Type I error rates were evaluated, for a total variant frequency (‘‘Freq.’’) of
0.05 and 0.01 with 5, 10, and 20 variants. Pearson c2 test and logistic
regression were applied on the collapsed data. Hotelling’s T2 test and
logistic regression were applied on data that were not collapsed. Results
are based on 5000 replicates.
a Sample size of 250 cases and 250 controls.
b Sample size of 1000 cases and 1000 controls.The Americanerror is inﬂated. This inﬂation increases with decreasing
allele frequencies (Table 1). For the CMC method, when
either the multivariate Hotelling’s T2 test or logistic regres-
sion is used for analysis of the data, the type I error is well
controlled (Table 2).
Analysis of Functional Variants
For a total locus variant frequency of 0.01 and a locus RR of
2.0, the power is the lowest for the single-marker test, with
an increase in power for the multiple-marker test (Hotel-
ling’s T2) and the greatest power observed for the collaps-
ing method (analysis of the collapsed genotypes with the
use of the Pearson c2 test statistic). When there are ten var-
iants within the locus, the power is 0.05, 0.39, and 0.83 for
the single-marker test, Hotelling’s T2 test, and the collaps-
ing method, respectively (Table 3). As the number of vari-
ants within the locus is increased from 5 to 20, the power
for both the single-marker test and the multiple-marker
test decreases but, conversely, the power for the collapsing
method increases (Table 3; Figure S1). For example, when
the total locus variant frequency is 0.05 and the number
of variants is increased from 5 to 20, the power for the sin-
gle-marker test decreases from 0.14 to 0.02, the power for
Hotelling’s T2 test decreases from 0.52 to 0.25, and the
power for the collapsing method increases from 0.81 to
0.88. This effect holds when the total locus variant fre-
quency is decreased to 0.01, when one variant’s frequency
is half of the total variant frequency and the other variant
frequencies are equal, and when half of the variants have
a locus RR of 3.0 and the remaining variants have a lower
locus RR (e.g., 2.0 or 1.5) (Table 3). For these situations, the
power of the single-marker test is always the smallest of the
three tests. Increasing the frequency of one of the variants
to half of the total variant frequency increases the power of
the single-marker test, whereas the power for the other
tests remains approximately the same (Table 3).
Table 2. Type I Error Rates at the a Level of 0.05 for the CMC
Method
Minor-Allele Frequency of a High-Frequency Variant
0.02 0.05
Freq.
No. of
Variants Hotelling’s T2
Logistic
Reg. Hotelling’s T2
Logistic
Reg.
0.05a 5 0.050 0.055 0.051 0.054
10 0.050 0.055 0.050 0.053
20 0.043 0.048 0.049 0.052
0.01b 5 0.052 0.054 0.055 0.057
10 0.051 0.052 0.051 0.055
20 0.049 0.053 0.049 0.050
Within the locus, there is one high-frequency variant with an allele
frequency of either 0.02 or 0.05 and 5, 10, or 20 rare variants with a total
variant frequency (‘‘Freq.’’) of 0.05 or 0.01. The CMC method was evaluated
with both Hotelling’s T2 test and logistic regression. Results are based on
5000 replicates.
a Sample size of 250 cases and 250 controls.
b Sample size of 1000 cases and 1000 controls.Journal of Human Genetics 83, 311–321, September 12, 2008 315
Table 3. The Power of the Single-Marker Test, Hotelling’s T2 Test, and the Collapsing Method
5 10 20
Freq. RR Model S H C S H C S H C
0.05a 2 equal freq. 0.14 0.52 0.81 0.05 0.40 0.86 0.02 0.25 0.88
unequal freq.c 0.24 0.52 0.81 0.20 0.40 0.85 0.17 0.25 0.87
unequal RRd 0.33 0.81 0.96 0.11 0.66 0.97 0.04 0.47 0.97
1.5 equal freq. 0.06 0.23 0.50 0.03 0.17 0.58 0.01 0.10 0.62
unequal freq. 0.10 0.23 0.50 0.08 0.17 0.57 0.06 0.10 0.61
unequal RR 0.32 0.75 0.94 0.10 0.56 0.93 0.03 0.38 0.94
0.01b 2 equal freq. 0.13 0.50 0.78 0.05 0.39 0.83 0.02 0.25 0.85
unequal freq. 0.23 0.50 0.78 0.20 0.39 0.83 0.16 0.25 0.85
unequal RR 0.34 0.82 0.96 0.11 0.67 0.96 0.04 0.49 0.97
1.5 equal freq. 0.05 0.20 0.45 0.02 0.15 0.53 0.01 0.08 0.57
unequal freq. 0.09 0.20 0.45 0.07 0.15 0.53 0.06 0.08 0.56
unequal RR 0.32 0.75 0.92 0.10 0.56 0.91 0.03 0.38 0.93
The power of the single-marker test (S), Hotelling’s T2 test (H), and the collapsing method (C) when there are 5, 10, or 20 causal variants within each locus
that have a total variant frequency of either 0.05 or 0.01. The analytical power is displayed for equal and unequal allele frequencies and for variants having
equal and unequal locus RR.
a Sample size of 250 cases and 250 controls.
b Sample size of 1000 cases and 1000 controls.
c One variant was assigned half of the total allele frequency, and the remaining variants have equal frequencies.
d Half of the variants were assigned an RR of 3.0, and the remaining variants have an RR of either 2.0 or 1.5.Misclassiﬁcation: Excluding Functional Variants
In the situation during which functional variants are ex-
cluded from the analysis, the power of the single-marker
test remains consistently low, whereas Hotelling’s T2 test
and the collapsing method decrease in power with the
increasing number of causal variants that are excluded
(Table 4, Figure S2). The collapsing method has much
greater power than does Hotelling’s T2 test when there
are no causal variants missing, but as the proportion of var-
iants excluded from the analysis increases, the power also
decreases more dramatically. For a total locus variant fre-
quency of 0.05, consisting of ten causal variants of equal
frequency and a locus RR of 2.0 when there are no variants
excluded, the power is 0.86 and 0.40 for the collapsing
method and Hotelling’s T2 test, respectively. When 20%
of the causal variants are excluded, the power falls to
0.72 and 0.31 for the collapsing method and Hotelling’s
T2 test, respectively. Even when 60% of the causal variants
are excluded, the collapsing method still has greater power
than does Hotelling’s T2 test (0.28 versus 0.12).
When high-frequency causal variants (e.g., those with
a frequency of 0.02 or 0.05) are excluded from the analysis,
the drop in power is most dramatic for the single-marker
test and Hotelling’s T2 test. For the single-marker test and
Hotelling’s T2 test, the power drops from 0.46 and 0.75
to 0.04 and 0.26, respectively, when a causal variant with
a frequency of 0.05 is excluded from the analysis. Al-
though the initial power is greater and the reduction in
power is not as large for the collapsing method, the de-
crease in power is not inconsequential. For example, the
power for the collapsing method falls from 0.95 to 0.81
when a functional variant with an allele frequency of
0.02 is excluded from the analysis. The reduction in power
is even more dramatic when an allele with a frequency of316 The American Journal of Human Genetics 83, 311–321, Septem0.05 is excluded from the analysis, with the power decreas-
ing from 0.99 to 0.73.
Misclassiﬁcation: Inclusion of Nonfunctional Variants
When nonfunctional rare variants with the same allele fre-
quencies as those of functional variants are included in the
analysis, power decreases for all three tests. The power for
the single-marker test is consistently low (Table 4, Fig-
ure S2). The power decreases more slowly for Hotelling’s
T2 test than for the collapsing method (Table 4, Figure S2).
As a result of the higher initial power of the collapsing
method, even when 20 nonfunctional rare variants with
frequencies of 0.005 are included in the analysis, the power
for the collapsing method (0.33) is still greater than the
power for Hotelling’s T2 test (0.16) (Table 4, Figure S2).
When one or more high-frequency noncausal variants
(e.g., those with a frequency of 0.02 or 0.05) are included
in the analysis, the power of the single-marker test remains
lower than that of both Hotelling’s T2 test and the collaps-
ing method. For Hotelling’s T2 test, although there is
a slight drop in power for each additional noncausal vari-
ant included in the analysis, the allele frequency of the
noncausal variant does not affect the power of the test.
For example, the power of Hotelling’s T2 test is 0.4 when
all variants are causal; when a nonfunctional variant is in-
cluded in the analysis, regardless of its allele frequency, the
power drops to 0.38, and the power falls slightly more to
0.36 when two nonfunctional variants are included. This
is not the case for collapsing method; the power decreases
with the increasing allele frequency of the nonfunctional
variant, and the decrease in power is even more drastic
when two high-frequency noncausal variants are included
in the analysis (Table 5, Figure S3). For the collapsing
method, the power decreases from 0.86 to 0.73 whenber 12, 2008
one noncausal variant with an allele frequency of 0.02 is
included in the analysis. The power decreases further, to
0.54, when the noncausal variant’s allele frequency is in-
creased to 0.05, and the power reduces further, to 0.32,
when two noncausal variants with allele frequencies of
0.05 are included in the analysis.
Power of the CMC Method
Variants that have an allele frequency % 0.01 are col-
lapsed, whereas variants with a frequency of > 0.01 are
not collapsed. There is a large increase in power if the
CMC method is used when there is misclassiﬁcation, as
compared to the collapsing method, particularly when
the allele frequency of the noncausal variant is high. For
example, when one noncausal variant with an allele fre-
quency of 0.05 is included in the analysis, the power for
the collapsing method, Hotelling’s T2 test, and the CMC
method is 0.54, 0.38, and 0.80, respectively (Table 5,
Figure S4). Although for the CMC method the allele fre-
quency of the noncausal allele does not affect the power,
the power is reduced as additional noncausal variants are
included in the analysis. However, the CMCmethod is still
more powerful than both the collapsing method and
Hotelling’s T2 test (Table 5, Figure S4). When two high-fre-
quency noncausal variants with allele frequencies of 0.05
are included in the analysis, the power is 0.74 for the
CMC method, 0.36 for Hotelling’s T2 test, and 0.32 for
the collapsing method (Table 5, Figure S4).
Also evaluated was how much power is lost when the
CMC method is used to analyze data in which high-
Table 4. The Power of the Single-Marker Test, Hotelling’s T2
Test, and the Collapsing Method when Noncausal Rare Variants
Are Included and Causal Rare Variants Are Excluded
Total Variant Frequency
0.05a 0.01b
No. Included S H C S H C
0 0.05 0.40 0.86 0.05 0.39 0.83
5 0.04 0.30 0.70 0.04 0.29 0.68
10 0.03 0.23 0.55 0.03 0.23 0.55
20 0.03 0.16 0.33 0.02 0.15 0.36
No. Excluded S H C S H C
2 0.05 0.31 0.72 0.05 0.30 0.69
4 0.05 0.21 0.52 0.04 0.20 0.50
6 0.04 0.12 0.28 0.04 0.12 0.27
8 0.03 0.05 0.08 0.03 0.05 0.08
The effect of including noncausal variants and excluding causal variants on
the power of the single-marker test (S), Hotelling’s T2 test (H), and the
collapsing method (C) when there are ten rare causal variants in a gene,
with a total variant frequency of either 0.05 or 0.01. In the upper section
of the table, also included in the analysis are 5, 10, and 20 rare noncausal
variants, with the same allele frequencies as the causal variants. In the
lower section of the table, 2, 4, 6, and 8 causal variants are excluded
from the analysis.
a Sample size of 250 cases and 250 controls.
b Sample size of 1000 cases and 1000 controls.The Americanfrequency variants included in the analysis are truly func-
tional. It is observed that for the CMC method, when two
functional variants are included in the analysis, there is
only a slight loss in power as compared to the collapsing
method (Table 5, Figure S5). For example, when two causal
variants with allele frequencies of 0.05 are included in the
analysis, the power for the collapsing method is 0.99. The
power drops to 0.98 when the CMC method is used to
analyze the data (Table 5, Figure S5).
Effect of Linkage Disequilibrium
In the presence of LD, the power for the single-marker test,
Hotelling’s T2 test, and the collapsing method is 0.075,
0.63, and 0.85, respectively. For the example in which
the data were generated with each variant on a separate
haplotype, the corresponding powers are 0.011, 0.451,
and 0.737, respectively.
Discussion
Before statistical analysis of sequence data can be carried
out, the ﬁrst step is quantifying which variants are poten-
tially functional or neutral. Bioinformatics tools24 such as
Polyphen,29 SIFT,30 and Evolutionary Trace31 can be used
to classify variants as potentially functional or neutral or
to quantify the certainty of the functionality. The results
obtained from bioinformatics tools can be used to deter-
mine which variants should be included in the analysis.
In an ideal situation, all variants that are included in the
analysis are functional and no functional variants are
excluded.
When there is no misclassiﬁcation of variants, the sin-
gle-marker test has the lowest power. Not only does this
Table 5. The Power of the Single-Marker Test, Hotelling’s T2
Test, the Collapsing Method, and the CMC Method when High-
Frequency Causal and Noncausal Variants Are Included in the
Analysis
No. of Variants Freq. S H C CMC
High-Frequency Functional Variants Included
0 NA 0.05 0.40 0.86 NA
1 0.02 0.13 0.57 0.95 0.91
1 0.05 0.46 0.75 0.99 0.97
2 0.02 0.16 0.69 0.98 0.93
2 0.05 0.51 0.86 0.99 0.98
High-Frequency Nonfunctional Variants Included
1 0.02 0.05 0.38 0.73 0.80
1 0.05 0.05 0.38 0.54 0.80
2 0.02 0.05 0.36 0.60 0.74
2 0.05 0.05 0.36 0.32 0.74
The power of the single-marker test (S), Hotelling’s T2 test (H), the collaps-
ing method (C), and the CMC method when there are ten rare causal vari-
ants, with a total variant frequency of 0.05, for a sample size of 250 cases
and 250 controls. Also included in the analysis are one or two high-
frequency causal or noncausal variants with an allele frequency of 0.02
or 0.05.Journal of Human Genetics 83, 311–321, September 12, 2008 317
test pay a penalty for multiple testing, but it is also affected
by the low allele frequency at each variant, where the
power for each individual c2 test is low. It should be noted
that Fisher’s exact test should be used instead of the c2 test
when the expected cell counts are low, in order to avoid in-
ﬂation of type I error. Because Fisher’s exact test is more
conservative than the c2 test, the power can be even lower
than that shown for the c2 test. The power for Hotelling’s
T2 test is superior to that for the single-marker test but is
less powerful than that for the collapsing method. The
improvement of power for the collapsing method is due
to an enrichment of signals across variants and the single
univariate test performed.
Although the highest power is obtained when all vari-
ants are correctly classiﬁed, it is unrealistic to assume,
even when bioinformatics tools are used for classiﬁcation
of functional status, that errors will not occur. Misclassiﬁ-
cation of rare variants does not have a dramatic effect on
power unless the functional status is incorrectly assigned
for a substantial number of variants. Retention of power
is observed when either rare functional variants are incor-
rectly removed from the analysis or nonfunctional variants
are included in the analysis. The exclusion of rare func-
tional variants has a more striking effect on the reduction
of power than does the inclusion of rare nonfunctional
variants.
When analyzing rare variants, high allele frequency is
not a sufﬁcient basis for excluding variants from the anal-
ysis. The allelic spectrum for complex disease is usually un-
known; however, a number of studies have demonstrated
that alleles with a wide range of frequencies are involved
in disease etiology.11–18,32 For example, for HDL choles-
terol it was recently shown that both common and rare
variants were responsible for modifying HDL cholesterol
levels.32 If high-frequency functional variants are removed
from the analysis, the effect on power can be extremely
detrimental, and if high-frequency nonfunctional variants
are included in the analysis and the collapsing method is
used, the power is also severely weakened. However, with
the use of CMC method, which applies a multivariate
test (e.g., Hotelling’s T2 test) on the collapsed rare variants
and the uncollapsed high-frequency variants, the high
power is retained even if the high-frequency variants are
nonfunctional. If the high-frequency variant is causal,
there is only a slight decrease in power with the use of
the CMC method as compared to the collapsing method.
Although the allele frequency of 0.01 was used for classiﬁ-
cation of rare and high-frequency variants, the cutoff is
subjective and dependent on the spectrum of the variant
frequency within a locus. This cutoff criterion might be
too high if the total allele frequency for the functional
variants is low (e.g., % 0.01). If a wide spectrum of allele
frequencies is observed, several cutoffs can be used for
the classiﬁcation of variants into multiple groups. Variants
that have very different allele frequencies should not be
collapsed into the same group, in order to avoid a substan-
tial loss of power when misclassiﬁcation is present.318 The American Journal of Human Genetics 83, 311–321, SeptemIf within a locus there are both rare and common func-
tional variants, use of the CMC method can increase
power, as compared to separate analysis of either the rare
variants or the common variants. Although in some cir-
cumstances there might be sufﬁcient power to detect an
association when a single common causal variant is ana-
lyzed, even for a functional variant with allele frequency
of R 0.05 the power to detect an association might be
low if the genotypic RR is small (e.g., 1.0 % RR % 1.2). In
the presence of common variants, it can be advantageous
to analyze both common and rare variants simultaneously
with the CMCmethod; including rare variants in the anal-
ysis can greatly increase power if the rare variants have
high genotypic RRs and are either numerous or not ex-
tremely rare. The amount of increase in power with the
CMC method will be dependent upon the total minor-
allele frequency of the rare variants, the strength of the
rare variants’ genotypic RRs, and the underlying genetic
model.
In this article, it is shown how the CMC method can be
used to analyze data on the basis of allele frequencies; e.g.,
on the basis of high-frequency or rare variants. The CMC
method can also be used when classiﬁcation is made on
the basis of certainty of functionality. For example, scores
from Polyphen, Evolutionary Trace, or SIFT can be used
to group variants into multiple classes depending on
user-deﬁned cutoffs that reﬂect their potential functional
role in disease etiology. Even when classiﬁcation is made
on the basis of conﬁdence in functionality, it is still in-
advisable to collapse rare and high-frequency variants
because, as previously discussed, if functionality classiﬁca-
tion is incorrect, then a large penalty in power can be in-
curred.
There is a caveat when collapsing rare variants across
multiple markers. When all of the functional variants con-
fer high risk or are protective, collapsing will enrich the
signal. However, the signal will be weakened if some vari-
ants are protective whereas others increase disease risk. Al-
though this situation is probably uncommon, when prior
information is available on high-risk and protective vari-
ants it should be taken into account when deciding how
to collapse variants, in order to obtain optimal power.
The CMC method can be applied when protective and
high-risk variants are collapsed separately.
Due to low allele frequencies of rare variants, the proba-
bility of individuals who are homozygous for the minor
allele being ascertained is extremely low. Therefore, even
though the locus RR for the multiplicative model (i.e.,
g2i ¼ g21i) is greater than the locus RR for the additive
model (i.e., g2i ¼ 2g1i  1), for all of the tests there is little
difference in power between these two models for rare var-
iants, with the power for the multiplicative model being
slightly higher than the additive model. Similarly, there
is only a slight increase in power for the additive model
compared to the dominant model (i.e., g2i ¼ g1i) (data
not shown). The situation is quite different for the reces-
sive model, in which the locus RR g1i ¼ 1 and g2i > 1.ber 12, 2008
Due to the rarity of homozygous genotypes for the minor
allele, very large sample sizes are necessary for sufﬁcient
power under the recessive model. For example, for g2i ¼
2.0, a total locus allele frequency of 0.05 with ten causal
variants and an a level of 0.001, a sample size of >
20,000 cases is necessary to obtain a power of 0.8 with
the collapsing method.
For rare variants, it is reasonable to assume that within
a locus they reside on different haplotypes.8,9 Under this
assumption, the frequency of haplotype hA1A2 is zero and
the LD between two rare variants is D ¼ p1p2z0 and
r2 ¼ D2=p1ð1 p1Þp2ð1 p2Þzp1p2z0, in which hA1A2 is
the haplotype of the two variants. Therefore, it is usually
reasonable to assume that the variants within a locus are
usually independent for power calculation. If this assump-
tion is violated and two functional variants are on the
same haplotype, the power is increased, because there is
a higher probability of carrying more than one functional
variant that increases the probability of an individual be-
ing a case. The application and the validity of the single-
marker test, Hotelling’s T2 test, the collapsing method,
and the CMC method are not altered by the presence of
LD. In the absence or presence of LD between rare variants,
the collapsing and CMC methods are more powerful than
Hotelling’s T2 test and the single-marker test.
A drawback of the described analysis methods is that co-
variates that could be potential confounders are not easily
controlled for in the analysis. It has been demonstrated for
association studies that it is important to control for poten-
tial confounders, including population stratiﬁcation.33 For
both the collapsing and CMC methods, this problem can
be overcome by implementing logistic regression, in which
covariates can be included in the analysis.
For all of the methods that were evaluated, type I error
was well controlled, except when logistic regression was
implemented to analyze uncollapsed rare variants (Table 1).
It is a well-known phenomenon that low cell counts or
empty cells can cause numerical instability of the maxi-
mum-likelihood estimation.34 When logistic-regression
analysis was applied to collapsed variants or to the CMC
method, type I error was well controlled; however, this
might not be the case if after collapsing the total allele fre-
quency is still very low. This problem can be circumvented
by estimation of empirical p values via permutation or use
of exact logistic regression.35,36
The collapsing method used in this article was based on
whether or not an individual had at least one copy of a rare
variant. There are other collapsing methods, involving
haplotype reconstruction, that can be used. One method
involves testing a 233 table, in which individuals are
classiﬁed as homozygous wild-type, having one or more
variants on the same haplotype and the other haplotype
containing only wild-type alleles, or having at least two
variants on different haplotypes. Another approach is to
test a 232 table, in which individual haplotypes are classi-
ﬁed into having at least one variant or no variants; in this
situation, the sample size is 2N. Both of these methods hadThe Americanpower similar to that of the collapsingmethod described in
this article (data not shown). It should be noted that for
the methods involving haplotype reconstruction, it was
assumed that the haplotypes were known. However, in re-
ality, haplotypes are not known with 100% accuracy, and
these errors in classiﬁcation will reduce power.
Although it is not necessary to correct for testing multi-
ple variants within a locus when the describedmethods are
used, if multiple regions are being tested, the FWER should
be controlled. The a value that should be used is depen-
dent on the number of tests that will be performed and
whether or not these tests are independent. Currently, for
whole genome association studies, a p value of 5 3 107
or smaller is used for genome-wide signiﬁcance, and this
criterion takes into consideration the correlation of the
common SNPs.37 For genome-wide association studies
that use sequence data, a more stringent criterion is neces-
sary because rare variants are not highly correlated. The
a level that should be used to sufﬁciently control type I
error for whole-genome sequence data is currently un-
known; however, it will be dependent not only on the
number of variants that are analyzed but also on how the
data is analyzed. For example, a more stringent criterion
would be necessary if every variant were analyzed sepa-
rately, compared to if variants across a locus were analyzed
simultaneously. The examples in this article are given for
a single locus, and an a level of 0.001 was used. However,
if more than one locus is being analyzed, a more stringent
a value would have to be used in order to control the
FWER.
In this study, the focus is on a locus with multiple vari-
ants and the main interest is the association of the locus
with the disease phenotype. In addition to allelic heteroge-
neity, locus heterogeneity will also be involved in the
etiology of complex traits. The methods described here
are able to detect multiple loci in the case of locus hetero-
geneity by analyzing individual loci separately. However,
the methods are not designed to detect gene 3 gene inter-
actions. The CMCmethod is a powerful and robust tool for
elucidating the main effects of susceptibility genes that are
involved in complex traits, for which the CDRV hypothe-
sis holds true. This method can be implemented with the
use of standard statistical software packages and readily ap-
plied to candidate-gene sequence data or extended for
analysis of whole-genome sequence data.
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